SCHEMBL24141990

SCHEMBL24141990

CNC(=O)CCC(=O)OC1CN(C(=O)CCCCCNC(=O)OC2CC[C@@]3(C)C(=CCC4C5CCC(C(C)CCCC(C)C)[C@@]5(C)CCC43)C2)CC1COC(c1ccccc1)(c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 1/20 0.45
PLA2G2A P14555 1/20 0.44
CYP46A1 Q9Y6A2 2/20 0.44
NR1H3 Q13133 4/20 0.42
APP P05067 1/20 0.42
EPHA2 P29317 4/20 0.40
NPC1L1 Q9UHC9 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
ABCB1 P08183 1/20 0.40
OSBP P22059 1/20 0.40
RORC P51449 1/20 0.40
OSBP2 Q969R2 1/20 0.40
GBA1 P04062 2/20 0.39
UGCG Q16739 2/20 0.39
GBA2 Q9HCG7 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4546174 1.00 POLA1 (0.45) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL15849326 1.00 POLA1 (0.45) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL837968 0.97 POLA1 (0.43) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL15186906 0.96 POLA1 (0.45) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL19272838 0.96 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL4546173 0.96 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL14652823 0.96 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL13556705 0.96 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL19152812 0.96 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP
SCHEMBL15959349 0.95 POLA1 (0.48) POLA1PLA2G2ACYP46A1NR1H3APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403917-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE ALNYLAM PHARMACEUTICALS, INC. (US) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403917-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE PCSK9, PCSK7, RNASE1 POLA1 326/4885PLA2G2A 493/4885CYP46A1 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.